甲氨蝶呤和7-羟基甲氨蝶呤暴露对儿童非霍奇金淋巴瘤肾毒性的影响。

IF 2.9 2区 医学 Q2 ONCOLOGY
Cancer Medicine Pub Date : 2025-01-16 DOI:10.1002/cam4.70516
Hao Bing, Yi Ma, Jiamin Xu, Qixian Ling, Yanlong Duan, Libo Zhao
{"title":"甲氨蝶呤和7-羟基甲氨蝶呤暴露对儿童非霍奇金淋巴瘤肾毒性的影响。","authors":"Hao Bing,&nbsp;Yi Ma,&nbsp;Jiamin Xu,&nbsp;Qixian Ling,&nbsp;Yanlong Duan,&nbsp;Libo Zhao","doi":"10.1002/cam4.70516","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>7-Hydroxymethotrexate (7-OHMTX) is the main metabolite in plasma following high-dose MTX (HD-MTX), which may result in activity and toxicity of the MTX. Moreover, 7-OHMTX could produce crystalline-like deposits within the renal tubules under acidic conditions or induce renal inflammation, oxidative stress, and cell apoptosis through various signaling pathways, ultimately leading to kidney damage. The objectives of this study were thus to explore the exposure–safety relationship of two compounds and search the most reliable marker for predicting HDMTX nephrotoxicity.</p>\n </section>\n \n <section>\n \n <h3> Method</h3>\n \n <p>A total of 280 plasma concentration data (140 for MTX and 140 for 7-OHMTX) for 60 pediatric patients with non-Hodgkin lymphoma (NHL) were prospectively collected. Plasma MTX and 7-OHMTX concentrations were determined using a high-performance liquid chromatography tandem mass spectrometry (HPLC–MS/MS) method. A nonlinear mixed effect model approach was used to build a joint population pharmacokinetic (PopPK) model. After validation, the model estimated the peak concentration (<i>C</i><sub>max</sub>) and area under the curve within the initial 48 h (AUC<sub>0-48h</sub>) of the patients after drug administration by Bayesian feedback. The receiver operating characteristic (ROC) curves were generated to identify an exposure threshold associated with nephrotoxicity.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A three-compartment chain model (central and peripheral compartments for MTX and central compartment 7-OHMTX) with the first-order elimination adequately characterized the in vivo process of MTX and 7-OHMTX. The covariate analysis identified that the aspartate aminotransferase (AST) was strongly associated with the peripheral volume of distribution of MTX. Moreover, the <i>C</i><sub>max</sub> of MTX and 7-OHMTX showed significant differences (<i>p</i> &lt; 0.0001, <i>p</i> = 0.0472, respectively) among patients with or without nephrotoxicity. Similarly, individuals with nephrotoxicity also exhibited substantially higher ratio of 7-OHMTX to MTX peak concentration and the sum of MTX + 2.25 times the concentration of 7-OHMTX (<i>p</i> &lt; 0.0001, <i>p</i> = 0.0426, respectively). By ROC analysis, the <i>C</i><sub>max</sub> of MTX and 7-OHMTX had the greatest area under the curve (AUC) values (0.769 and 0.771, respectively). A <i>C</i><sub>max</sub> threshold of 9.26 μmol/L for MTX or a <i>C</i><sub>max</sub> threshold of 0.66 μmol/L for 7-OHMTX was associated with the best sensitivity/specificity for toxicity events (MTX: sensitivity = 0.886; specificity = 0.70; 7-OHMTX: sensitivity = 0.886; specificity = 0.70).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>We demonstrated that the <i>C</i><sub>max</sub> of MTX and 7-OHMTX were the most reliable markers associated with nephrotoxicity and proposed a <i>C</i><sub>max</sub> threshold of 9.26 μmol/L for MTX and 0.66 μmol/L for 7-OHMTX as the point with a high risk of nephrotoxicity. Altogether, this study may contribute to crucial insights for ensuring the safe administration of drugs in pediatric clinical practice.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 2","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739129/pdf/","citationCount":"0","resultStr":"{\"title\":\"Impact of Methotrexate and 7-Hydroxymethotrexate Exposure on Renal Toxicity in Pediatric Non-Hodgkin Lymphoma\",\"authors\":\"Hao Bing,&nbsp;Yi Ma,&nbsp;Jiamin Xu,&nbsp;Qixian Ling,&nbsp;Yanlong Duan,&nbsp;Libo Zhao\",\"doi\":\"10.1002/cam4.70516\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>7-Hydroxymethotrexate (7-OHMTX) is the main metabolite in plasma following high-dose MTX (HD-MTX), which may result in activity and toxicity of the MTX. Moreover, 7-OHMTX could produce crystalline-like deposits within the renal tubules under acidic conditions or induce renal inflammation, oxidative stress, and cell apoptosis through various signaling pathways, ultimately leading to kidney damage. The objectives of this study were thus to explore the exposure–safety relationship of two compounds and search the most reliable marker for predicting HDMTX nephrotoxicity.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Method</h3>\\n \\n <p>A total of 280 plasma concentration data (140 for MTX and 140 for 7-OHMTX) for 60 pediatric patients with non-Hodgkin lymphoma (NHL) were prospectively collected. Plasma MTX and 7-OHMTX concentrations were determined using a high-performance liquid chromatography tandem mass spectrometry (HPLC–MS/MS) method. A nonlinear mixed effect model approach was used to build a joint population pharmacokinetic (PopPK) model. After validation, the model estimated the peak concentration (<i>C</i><sub>max</sub>) and area under the curve within the initial 48 h (AUC<sub>0-48h</sub>) of the patients after drug administration by Bayesian feedback. The receiver operating characteristic (ROC) curves were generated to identify an exposure threshold associated with nephrotoxicity.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>A three-compartment chain model (central and peripheral compartments for MTX and central compartment 7-OHMTX) with the first-order elimination adequately characterized the in vivo process of MTX and 7-OHMTX. The covariate analysis identified that the aspartate aminotransferase (AST) was strongly associated with the peripheral volume of distribution of MTX. Moreover, the <i>C</i><sub>max</sub> of MTX and 7-OHMTX showed significant differences (<i>p</i> &lt; 0.0001, <i>p</i> = 0.0472, respectively) among patients with or without nephrotoxicity. Similarly, individuals with nephrotoxicity also exhibited substantially higher ratio of 7-OHMTX to MTX peak concentration and the sum of MTX + 2.25 times the concentration of 7-OHMTX (<i>p</i> &lt; 0.0001, <i>p</i> = 0.0426, respectively). By ROC analysis, the <i>C</i><sub>max</sub> of MTX and 7-OHMTX had the greatest area under the curve (AUC) values (0.769 and 0.771, respectively). A <i>C</i><sub>max</sub> threshold of 9.26 μmol/L for MTX or a <i>C</i><sub>max</sub> threshold of 0.66 μmol/L for 7-OHMTX was associated with the best sensitivity/specificity for toxicity events (MTX: sensitivity = 0.886; specificity = 0.70; 7-OHMTX: sensitivity = 0.886; specificity = 0.70).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>We demonstrated that the <i>C</i><sub>max</sub> of MTX and 7-OHMTX were the most reliable markers associated with nephrotoxicity and proposed a <i>C</i><sub>max</sub> threshold of 9.26 μmol/L for MTX and 0.66 μmol/L for 7-OHMTX as the point with a high risk of nephrotoxicity. Altogether, this study may contribute to crucial insights for ensuring the safe administration of drugs in pediatric clinical practice.</p>\\n </section>\\n </div>\",\"PeriodicalId\":139,\"journal\":{\"name\":\"Cancer Medicine\",\"volume\":\"14 2\",\"pages\":\"\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-01-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739129/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70516\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70516","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:7-羟基甲氨蝶呤(7-OHMTX)是高剂量MTX (HD-MTX)后血浆中的主要代谢物,可能导致MTX的活性和毒性。此外,在酸性条件下,7-OHMTX可在肾小管内产生结晶样沉积物,或通过多种信号通路诱导肾脏炎症、氧化应激和细胞凋亡,最终导致肾脏损伤。因此,本研究的目的是探讨两种化合物的暴露-安全关系,并寻找预测HDMTX肾毒性的最可靠的标志物。方法:前瞻性收集60例非霍奇金淋巴瘤(NHL)患儿280份血药浓度数据(MTX为140份,7-OHMTX为140份)。采用高效液相色谱-串联质谱(HPLC-MS/MS)法测定血浆MTX和7-OHMTX浓度。采用非线性混合效应模型方法建立联合群体药代动力学(PopPK)模型。验证后,模型通过贝叶斯反馈估计患者给药后最初48h (AUC0-48h)内的峰浓度(Cmax)和曲线下面积。生成受试者工作特征(ROC)曲线,以确定与肾毒性相关的暴露阈值。结果:一阶消除的三室链模型(MTX的中央和外周室和7-OHMTX的中央室)充分表征了MTX和7-OHMTX的体内过程。协变量分析表明,天冬氨酸转氨酶(AST)与MTX的外周分布体积密切相关。MTX和7-OHMTX的Cmax差异显著,其中MTX和7-OHMTX的p max曲线下面积(AUC)值最大,分别为0.769和0.771。MTX的Cmax阈值为9.26 μmol/L, 7-OHMTX的Cmax阈值为0.66 μmol/L,对毒性事件的敏感性/特异性最佳(MTX:敏感性= 0.886;特异性= 0.70;7-OHMTX:灵敏度= 0.886;特异性= 0.70)。结论:MTX和7-OHMTX的Cmax是最可靠的肾毒性标志物,并提出MTX的Cmax阈值为9.26 μmol/L, 7-OHMTX的Cmax阈值为0.66 μmol/L作为肾毒性的高危点。总之,这项研究可能有助于确保儿科临床实践中药物安全管理的重要见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Impact of Methotrexate and 7-Hydroxymethotrexate Exposure on Renal Toxicity in Pediatric Non-Hodgkin Lymphoma

Background

7-Hydroxymethotrexate (7-OHMTX) is the main metabolite in plasma following high-dose MTX (HD-MTX), which may result in activity and toxicity of the MTX. Moreover, 7-OHMTX could produce crystalline-like deposits within the renal tubules under acidic conditions or induce renal inflammation, oxidative stress, and cell apoptosis through various signaling pathways, ultimately leading to kidney damage. The objectives of this study were thus to explore the exposure–safety relationship of two compounds and search the most reliable marker for predicting HDMTX nephrotoxicity.

Method

A total of 280 plasma concentration data (140 for MTX and 140 for 7-OHMTX) for 60 pediatric patients with non-Hodgkin lymphoma (NHL) were prospectively collected. Plasma MTX and 7-OHMTX concentrations were determined using a high-performance liquid chromatography tandem mass spectrometry (HPLC–MS/MS) method. A nonlinear mixed effect model approach was used to build a joint population pharmacokinetic (PopPK) model. After validation, the model estimated the peak concentration (Cmax) and area under the curve within the initial 48 h (AUC0-48h) of the patients after drug administration by Bayesian feedback. The receiver operating characteristic (ROC) curves were generated to identify an exposure threshold associated with nephrotoxicity.

Results

A three-compartment chain model (central and peripheral compartments for MTX and central compartment 7-OHMTX) with the first-order elimination adequately characterized the in vivo process of MTX and 7-OHMTX. The covariate analysis identified that the aspartate aminotransferase (AST) was strongly associated with the peripheral volume of distribution of MTX. Moreover, the Cmax of MTX and 7-OHMTX showed significant differences (p < 0.0001, p = 0.0472, respectively) among patients with or without nephrotoxicity. Similarly, individuals with nephrotoxicity also exhibited substantially higher ratio of 7-OHMTX to MTX peak concentration and the sum of MTX + 2.25 times the concentration of 7-OHMTX (p < 0.0001, p = 0.0426, respectively). By ROC analysis, the Cmax of MTX and 7-OHMTX had the greatest area under the curve (AUC) values (0.769 and 0.771, respectively). A Cmax threshold of 9.26 μmol/L for MTX or a Cmax threshold of 0.66 μmol/L for 7-OHMTX was associated with the best sensitivity/specificity for toxicity events (MTX: sensitivity = 0.886; specificity = 0.70; 7-OHMTX: sensitivity = 0.886; specificity = 0.70).

Conclusions

We demonstrated that the Cmax of MTX and 7-OHMTX were the most reliable markers associated with nephrotoxicity and proposed a Cmax threshold of 9.26 μmol/L for MTX and 0.66 μmol/L for 7-OHMTX as the point with a high risk of nephrotoxicity. Altogether, this study may contribute to crucial insights for ensuring the safe administration of drugs in pediatric clinical practice.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cancer Medicine
Cancer Medicine ONCOLOGY-
CiteScore
5.50
自引率
2.50%
发文量
907
审稿时长
19 weeks
期刊介绍: Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信